First-Year Healthcare Resource Utilization Costs of Five Major Cancers in Japan.
Japan
healthcare costs
major cancers
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
07 09 2021
07 09 2021
Historique:
received:
28
07
2021
revised:
02
09
2021
accepted:
04
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Reports on the expenditure of cancer treatments per patient using comprehensive data remain unavailable in Japan. This study aimed to use Japan's cancer registry data and health service utilization data for evaluating the disease-specific, per-patient costs of five major cancers-stomach, lung, colorectal, liver, and breast cancers. We used a database linking the 2017 data from a hospital-based cancer registry and the health service utilization data from the Diagnosis Procedure Combination survey. All patients who started their first treatment course at each hospital were included. The costs were calculated using the total volume of the health services provided and the unit fee information included in the data. We analyzed 304,698 patients. Lung cancer had the highest healthcare cost per-patient for the first year of diagnosis and the longest median hospitalization duration. Conversely, breast cancer showed the lowest cost and the shortest median hospitalization duration. However, in the first month after diagnosis, colorectal cancer showed the highest cost. Subsequently, the gaps between the costs of the five common cancers drastically diminished. The cancer type having the longest hospitalization duration had the highest overall healthcare resource utilization costs. This information is essential for care planning and research studies.
Identifiants
pubmed: 34574371
pii: ijerph18189447
doi: 10.3390/ijerph18189447
pmc: PMC8466127
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Sci. 2016 Jan;107(1):68-75
pubmed: 26495806
Int Heart J. 2005 Sep;46(5):855-66
pubmed: 16272776
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
Pharmacoeconomics. 2013 Jul;31(7):577-88
pubmed: 23636661
Z Evid Fortbild Qual Gesundhwes. 2009;103(6):305-16
pubmed: 19839202
Lancet Oncol. 2011 Sep;12(10):933-80
pubmed: 21958503
J Thorac Dis. 2011 Sep;3(3):183-8
pubmed: 22263086
Am J Med. 2000 Oct 1;109(5):378-85
pubmed: 11020394
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614
PLoS One. 2018 Jul 30;13(7):e0201552
pubmed: 30059534
Value Health. 2017 Mar;20(3):372-378
pubmed: 28292481
Jpn J Clin Oncol. 2014 Jan;44(1):2-8
pubmed: 23448800
BMC Health Serv Res. 2016 Jan 04;16:2
pubmed: 26728154
Int J Health Serv. 1999;29(1):189-209
pubmed: 10079404
Med Care. 2015 Apr;53(4):302-9
pubmed: 25749656
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
J Gynecol Oncol. 2018 Nov;29(6):e83
pubmed: 30207093